Phase II Trial of Romiplostim for Thrombocytopenia Induced by Lomustine at First Progression of MGMT Promoter-meth Glioblastoma

NCT04933942 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

NETWORK

Sponsor class

Stopped Amgen withdrew interest in providing further financial support

Conditions

First Progression of MGMT Promoter-methylated Glioblastoma

Interventions

DRUG: Lomustine
DRUG: Romiplostim

Sponsor

European Organisation for Research and Treatment of Cancer - EORTC

Collaborators

[object Object]